JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

4.42 -3.49

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.35

Max

4.55

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-39M

-44M

Pardavimai

9.8M

62M

Pelno marža

-70.929

Darbuotojai

702

EBITDA

4M

-263K

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+40.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

12M

573M

Ankstesnė atidarymo kaina

7.91

Ankstesnė uždarymo kaina

4.42

Naujienos nuotaikos

By Acuity

50%

50%

177 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Cytek Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-28 23:33; UTC

Karštos akcijos

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

2026-04-28 23:24; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

2026-04-28 23:15; UTC

Svarbiausios naujienos

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

2026-04-28 22:46; UTC

Uždarbis

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

2026-04-28 22:37; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

2026-04-28 22:15; UTC

Uždarbis
Svarbiausios naujienos

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

2026-04-28 23:33; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

2026-04-28 23:31; UTC

Uždarbis

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

2026-04-28 23:30; UTC

Uždarbis

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

2026-04-28 23:19; UTC

Rinkos pokalbiai
Uždarbis

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

2026-04-28 23:09; UTC

Uždarbis

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

2026-04-28 23:03; UTC

Rinkos pokalbiai

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees One Rate Rise to 4% in Benign Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

2026-04-28 23:01; UTC

Svarbiausios naujienos

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

2026-04-28 22:51; UTC

Uždarbis

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

2026-04-28 22:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-28 22:48; UTC

Rinkos pokalbiai

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

2026-04-28 22:40; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

2026-04-28 22:32; UTC

Uždarbis

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

2026-04-28 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Pernod Ricard and Brown-Forman End Deal Talks -- Update

2026-04-28 22:22; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

2026-04-28 22:17; UTC

Rinkos pokalbiai

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

2026-04-28 22:14; UTC

Uždarbis

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

2026-04-28 22:07; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Akcijų palyginimas

Kainos pokytis

Cytek Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

40.13% į viršų

12 mėnesių prognozė

Vidutinis 6.25 USD  40.13%

Aukščiausias 7.5 USD

Žemiausias 5 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cytek Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.7 / 3.8Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

177 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat